Clinical Research on NMN

Below is a comprehensive list of peer-reviewed human clinical trials and systematic reviews investigating nicotinamide mononucleotide (NMN) supplementation.
All citations have been verified from PubMed or journal sources.

---

Key Verified Human Trials

Yoshino et al., 2021 – Washington University (published in Science)

Design: Randomised, double-blind, placebo-controlled trial
Participants: 25 post-menopausal women with prediabetes
Dose: 250 mg NMN daily for 10 weeks
Findings: Increased skeletal-muscle insulin sensitivity by approximately 25 % versus placebo, with no serious adverse events.
🔗 PubMed: 33888596

---

Irie et al., 2020 – Early Safety and Pharmacokinetics

Journal: Endocrine Journal
Design: Single- and short-term dose escalation in healthy Japanese men
Dose: 100 – 500 mg NMN orally
Findings: Well tolerated; dose-related rises in blood nicotinamide metabolites.
🔗 PubMed: 31748405

---

Okabe et al., 2022 – NAD⁺ Elevation in Healthy Adults

Journal: Frontiers in Nutrition
Design: 12-week randomised, placebo-controlled trial (30 participants)
Dose: 250 mg NMN daily
Findings: Significant rise in blood NAD⁺; no adverse events.
🔗 PubMed: 35479740

---

Igarashi et al., 2022 – Older Men, Muscle Function

Journal: NPJ Aging
Design: 12-week randomised, double-blind, placebo-controlled trial
Dose: 250 mg NMN daily
Findings: Elevated blood NAD⁺ and modest improvements in muscle function.
🔗 PubMed: 35927255

---

Fukamizu et al., 2022 – High-Dose Safety (1,250 mg/day)

Journal: Scientific Reports
Design: Four-week randomised, placebo-controlled study, 31 adults
Findings: No serious adverse events; laboratory parameters remained normal.
🔗 PubMed: 35999583

---

Katayoshi et al., 2023 – Arterial Stiffness and NAD⁺ Metabolism

Journal: Scientific Reports
Design: 12-week randomised, double-blind, placebo-controlled
Dose: 125 mg twice daily (250 mg total)
Findings: Increased NAD⁺-related metabolites; mild improvements in vascular parameters.
🔗 PubMed: 37344088

---

Yi et al., 2023 – Dose-Response NAD⁺ Study

Journal: Geroscience
Design: 60-day randomised, multicentre trial (80 adults)
Doses: 300, 600 and 900 mg/day
Findings: Clear dose-dependent rise in blood NAD⁺; good safety profile.
🔗 PubMed: 36482258

---

Kim et al., 2022 – Sleep, Fatigue and Physical Performance

Journal: Nutrients
Design: 12-week randomised, placebo-controlled study (108 older adults)
Dose: 250 mg/day
Findings: Improved walking speed and fatigue scores, particularly with afternoon dosing.
🔗 PubMed: 35215405

---

Liao et al., 2021 – Aerobic Capacity in Amateur Runners

Journal: Journal of the International Society of Sports Nutrition
Design: 6-week randomised, double-blind trial
Doses: 300 – 1,200 mg/day
Findings: Dose-dependent improvements in VO₂ max and muscle oxygen use.
🔗 PubMed: 34238308

---

Huang et al., 2022 – ‘Uthever’ NMN in Middle-Aged Adults

Journal: Frontiers in Aging
Design: 60-day multicentre, double-blind, placebo-controlled study
Dose: 300 mg/day
Findings: Improved six-minute walk distance and self-reported health metrics.
🔗 Full text

---

Yamaguchi et al., 2024 – Long-Term Safety in Older Adults

Journal: Endocrine Journal
Design: Extended-duration NMN supplementation study
Findings: Continued safety over longer use; mild benefits to blood pressure and metabolic markers.
🔗 Full text

---

Systematic Reviews and Meta-Analyses

Song et al., 2023 – Safety and Anti-Ageing Review

Advances in Nutrition
Summary of all human NMN trials to date. Concluded NMN consistently increases NAD⁺ and is well-tolerated up to 1,250 mg/day, though clinical efficacy remains uncertain.
🔗 PubMed: 37619764

---

Zhang et al., 2025 – Glucose and Lipid Metabolism

Critical Reviews in Food Science and Nutrition
Meta-analysis of RCTs assessing fasting glucose, insulin resistance and lipids. Found modest metabolic effects and clear NAD⁺ elevation.
🔗 PubMed: 39116016

---

Wen et al., 2024 – Physical Performance Outcomes

Cureus
Systematic review of RCTs focusing on strength, walking speed and VO₂ max. Found small improvements in certain metrics, with high heterogeneity.
🔗 PubMed: 39221308

---

Prokopidis et al., 2025 – NMN / NR and Muscle Function

Journal of Cachexia, Sarcopenia and Muscle
Meta-analysis of NMN and NR supplementation in older adults. Concluded no significant effect on muscle mass or strength overall.
🔗 Full text (PMC)

---

Liao et al., 2024 – Broad Clinical Overview

Journal of Translational Medicine
Comprehensive review of NMN pre-clinical and clinical studies, mechanisms, and potential applications in age-related disease.
🔗 Full text

---

Summary

---